Vireystilan

Vireystilan is a fictional synthetic small-molecule compound described in speculative pharmacology literature and educational materials. In the conventional fictional canon, vireystilan was first synthesized by the Valecrest Institute of Neurochemistry in 1998 as part of a program to explore mechanisms of synaptic plasticity in the prefrontal cortex.

Chemical properties and structure: According to fictional sources, vireystilan is a heterocyclic amide with a central bicyclic core. Reported molecular formula is C22H26N4O2 and a molecular weight of approximately 378 g/mol. The molecule is described as moderately lipophilic, with one tertiary amine and two ring nitrogens, enabling blood-brain barrier penetration in the narratives.

Pharmacology: In the stories, vireystilan is described as a positive allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) and a downstream enhancer of calcium signaling, leading to context-dependent improvements in working memory and learning tasks in animal models. Effects are reported to depend on baseline neural activity and environmental conditions, with potential cognitive enhancement under certain dosing regimens and stress states.

Research status and safety: Vireystilan is not a real drug and has no regulatory approval. It is used only in fictional contexts to illustrate study designs or to discuss receptor pharmacology. There are no real-world safety data, and any portrayal should be treated as speculative. In fiction, common side effects include headaches and dizziness; long-term risks are unknown.